Telix Pharmaceuticals (NASDAQ:TLX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $20.00 target price on the stock.

Several other analysts also recently weighed in on TLX. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Citigroup increased their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen downgraded shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX opened at $9.63 on Tuesday. The firm’s 50-day moving average price is $7.76 and its 200-day moving average price is $8.71. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $20.00.

Telix Pharmaceuticals (NASDAQ:TLX) last posted its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The company had revenue of $206.72 million during the quarter, compared to the consensus estimate of $421.50 million. On average, sell-side analysts anticipate that Telix Pharmaceuticals will post 0.24 EPS for the current year.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TLX. Russell Investments Group Ltd. purchased a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $975,000. Jane Street Group LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $564,000. IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $213,000. Rhumbline Advisers boosted its holdings in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Telix Pharmaceuticals during the 3rd quarter valued at about $243,000.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Company Q1 2026 update reports strong revenue growth, continued commercial traction and advancement of its therapeutics pipeline; guidance was reaffirmed, which supports the stock’s rally. Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
• Positive Sentiment: Wedbush reaffirmed an Outperform rating with a $22 price target, signaling strong analyst confidence in Telix’s growth trajectory and providing material upside versus the current share level. This call is being cited as a key driver of today’s buying. Why Is Telix Pharma Stock Soaring?
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating with a $20 target, another supportive broker view that reinforces upside expectations among investors. HC Wainwright Buy Rating
• Positive Sentiment: Press and analyst commentary highlight further upside scenarios — some coverage projects additional gains (one piece argues shares could still rise ~40%), which can attract momentum buyers. Why rebounding Telix shares could still rise 40%
• Neutral Sentiment: Analyst consensus remains cautiously positive (reported as a “Moderate Buy”), indicating broad but measured support rather than unanimous conviction. Consensus Rating: Moderate Buy
• Negative Sentiment: Remains a risk: recent quarterly results showed an EPS miss and revenue below some street expectations earlier this year, which investors should weigh against the upbeat guidance and analyst notes. Recent EPS and revenue miss (background)

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.